carvedilol has been researched along with Stroke in 12 studies
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 9.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Aim of the study was to elucidate peculiarities of influence of carvedilol on 24-hour blood pressure (BP) profiles and changes of parameters of cerebral perfusion in patients with arterial hypertension (AH) associated with type 2 diabetes mellitus." | 7.74 | [Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus]. ( Belokopytova, NV; Efimova, IIu; Fal'kovskaia, AIu; Mordovin, VF, 2007) |
| "The datasets included in this pooling initiative were derived from 4 trials: CAPRICORN (Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction), OPTIMAAL (Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan), VALIANT (Valsartan in Acute Myocardial Infarction Trial), and EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study); EPHESUS was used for external validation." | 5.27 | Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. ( Abdul-Rahim, AH; Dickstein, K; Ferreira, JP; Girerd, N; Gregson, J; Latar, I; McMurray, JJV; Pfeffer, MA; Pitt, B; Rossignol, P; Sharma, A; Zannad, F, 2018) |
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 5.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Aim of the study was to elucidate peculiarities of influence of carvedilol on 24-hour blood pressure (BP) profiles and changes of parameters of cerebral perfusion in patients with arterial hypertension (AH) associated with type 2 diabetes mellitus." | 3.74 | [Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus]. ( Belokopytova, NV; Efimova, IIu; Fal'kovskaia, AIu; Mordovin, VF, 2007) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| " The number and type of antihypertensive drugs have increased dramatically from 28 diuretics in 1972 to over 125 agents today, including fixed dose combination dosage forms." | 1.36 | The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. ( Black, HR; Greenberg, BH; Weber, MA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, T | 1 |
| Madge, DJ | 1 |
| Mulla, M | 1 |
| Riddall, D | 1 |
| Ferreira, JP | 1 |
| Girerd, N | 1 |
| Gregson, J | 1 |
| Latar, I | 1 |
| Sharma, A | 1 |
| Pfeffer, MA | 1 |
| McMurray, JJV | 1 |
| Abdul-Rahim, AH | 1 |
| Pitt, B | 1 |
| Dickstein, K | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| Black, HR | 1 |
| Greenberg, BH | 1 |
| Weber, MA | 1 |
| Fleming, T | 1 |
| Borer, J | 1 |
| Armstrong, PW | 1 |
| Pfeffer, M | 1 |
| Yamagata, K | 1 |
| Ichinose, S | 1 |
| Tagami, M | 1 |
| Krauser, DG | 1 |
| Devereux, RB | 1 |
| Remme, WJ | 1 |
| Torp-Pedersen, C | 1 |
| Cleland, JG | 1 |
| Poole-Wilson, PA | 1 |
| Metra, M | 1 |
| Komajda, M | 1 |
| Swedberg, K | 1 |
| Di Lenarda, A | 1 |
| Spark, P | 1 |
| Scherhag, A | 1 |
| Moullet, C | 1 |
| Lukas, MA | 1 |
| Mordovin, VF | 1 |
| Belokopytova, NV | 1 |
| Fal'kovskaia, AIu | 1 |
| Efimova, IIu | 1 |
| Intengan, HD | 1 |
| Schiffrin, EL | 1 |
| Savitz, SI | 1 |
| Erhardt, JA | 1 |
| Anthony, JV | 1 |
| Gupta, G | 1 |
| Li, X | 1 |
| Barone, FC | 2 |
| Rosenbaum, DM | 1 |
| Ma, XL | 1 |
| Gao, F | 1 |
| Nelson, AH | 1 |
| Lopez, BL | 1 |
| Christopher, TA | 1 |
| Yue, TL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carvedilol and Stroke
| Article | Year |
|---|---|
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Mo | 2001 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
2 trials available for carvedilol and Stroke
| Article | Year |
|---|---|
Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Carvedilol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocard | 2018 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
8 other studies available for carvedilol and Stroke
| Article | Year |
|---|---|
The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Cardiovascular Diseas | 2010 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca | 2003 |
Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antioxidants; Carbazoles; Carvedilol; Cell Death; Cell Hypoxia; Cells, Cultured | 2004 |
[Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Blood Pressure Mon | 2007 |
Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Endothelium, | 2000 |
[Beta blocker therapy for elderly hypertensive patients].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Hemodynamics; Humans; Hypertension; Propa | 2000 |
The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Brain; Carbazoles; Carvedilol; Cerebral Cortex; Cer | 2000 |
Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Apoptosis; Blood Pressure; Car | 2001 |